These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1729 related articles for article (PubMed ID: 25037117)
1. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Beck JT; Ismail A; Tolomeo C Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117 [TBL] [Abstract][Full Text] [Related]
2. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Fumarola C; Bonelli MA; Petronini PG; Alfieri RR Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259 [TBL] [Abstract][Full Text] [Related]
3. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Gadgeel SM; Wozniak A Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287 [TBL] [Abstract][Full Text] [Related]
4. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Sun Z; Wang Z; Liu X; Wang D Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988 [TBL] [Abstract][Full Text] [Related]
5. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Mabuchi S; Kuroda H; Takahashi R; Sasano T Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064 [TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Zhou Q; Lui VW; Yeo W Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728 [TBL] [Abstract][Full Text] [Related]
7. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Polivka J; Janku F Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502 [TBL] [Abstract][Full Text] [Related]
8. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080 [TBL] [Abstract][Full Text] [Related]
9. Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis. Chen J; Crawford R; Xiao Y J Cell Biochem; 2013 Feb; 114(2):245-9. PubMed ID: 22930581 [TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Simpson DR; Mell LK; Cohen EE Oral Oncol; 2015 Apr; 51(4):291-8. PubMed ID: 25532816 [TBL] [Abstract][Full Text] [Related]
11. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Gonzalez-Angulo AM; Blumenschein GR Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708 [TBL] [Abstract][Full Text] [Related]
12. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Wolin EM Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523 [TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers? Zardavas D; Fumagalli D; Loi S Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556 [TBL] [Abstract][Full Text] [Related]
14. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details. Myers AP Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439 [TBL] [Abstract][Full Text] [Related]
15. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Blachly JS; Baiocchi RA Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567 [TBL] [Abstract][Full Text] [Related]
16. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Li H; Zeng J; Shen K Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744 [TBL] [Abstract][Full Text] [Related]
17. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. Bartalucci N; Guglielmelli P; Vannucchi AM Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217 [TBL] [Abstract][Full Text] [Related]
18. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Slomovitz BM; Coleman RL Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003 [TBL] [Abstract][Full Text] [Related]
19. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer. Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612 [TBL] [Abstract][Full Text] [Related]
20. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition. Jin HO; Lee YH; Park JA; Kim JH; Hong SE; Kim HA; Kim EK; Noh WC; Kim BH; Ye SK; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK Biochem Biophys Res Commun; 2014 Feb; 444(4):502-8. PubMed ID: 24472538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]